Clinical trials: Prostate Disease
Lung Cancer, Breast Cancer
Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases
For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00581113
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11.25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in…
- Trial name
- PAMIS (NCT01257425)
- Testing
- Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
- Where
- 22 sites in Germany
- Volunteers
- 109 people
- Sponsor
- Ipsen
Prostate Neoplasm
Role of Soy Supplementation in Prostate Cancer Development
This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue.
- Trial name
- NCT00255125
- Testing
- Soy Supplement
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Prostate Cancer
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Primary Objectives: To determine the maximum tolerated dose, and dose limiting toxicities of cabazitaxel administered as a 1-hour infusion every 3 weeks in combination with oral daily abiraterone acetate and prednisone in…
- Trial name
- NCT01511536
- Testing
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).
- Trial name
- TRIUMPH-1 (NCT00889707)
- Testing
- PRX302
- Where
- 9 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Ketoconazole and Dexamethasone in Prostate Cancer
This is an open label, phase II, single center trial of ketoconazole/dexamethasone to determine if the administration of ketoconazole/dexamethasone, after disease progression with ketoconazole/hydrocortisone slows or reverses…
- Trial name
- Keto/Dex (NCT01036594)
- Testing
- Ketoconazole, Hydrocortisone, Dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC.
- Trial name
- NCT04191096
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 234 sites in United States, Australia and 27 more
- Volunteers
- 1,251 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer of Prostate, Cancer of the Prostate
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
NC ProCESS is a cohort of patients from diverse backgrounds diagnosed with early prostate cancer, who were enrolled from January 2011-June 2013.
- Conditions
- Cancer of Prostate, Cancer of the Prostate, Prostate Cancer, Prostatic Cancer
- Trial name
- NCT02564120
- Where
- United States
- Volunteers
- 1,556 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT01253642
- Testing
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
1. The investigators hypothesize that increasing radiation dose to the functional MRI-defined lesion in the prostate bed will result in an improved initial complete response (reduction in prostate-specific antigen (PSA) to < 0.1…
- Trial name
- MAPS (NCT01411345)
- Testing
- Standard Salvage Radiation Treatment (SSRT), Mapped Tumor Salvage RT (MTSRT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Miami
Metastatic Prostate Cancer
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
- Trial name
- NCT01981122
- Testing
- sipuleucel-T, enzalutamide
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dendreon
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Background: Currently, there is no curative therapy for metastatic castrate-resistant prostate cancer (CRPC), a leading cause of death in men.
- Trial name
- NCT01090765
- Testing
- TRC105
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
The purpose of this study is to find out what effects taking ipilimumab, as an immediate or delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and their prostate cancer.
- Trial name
- NCT01804465
- Testing
- SipT Treatment, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).
- Trial name
- REZUM (NCT01912339)
- Testing
- Rezum System, Rigid Cystoscopy
- Where
- 15 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boston Scientific Corporation
Prostatic Neoplasms
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination…
- Trial name
- AMPLITUDE (NCT04497844)
- Testing
- Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone
- Where
- 387 sites in United States, Argentina and 31 more
- Volunteers
- 696 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.
- Trial name
- NCT00183937
- Testing
- PS 341, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Prostate Cancer
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
- Trial name
- GTx758 (NCT01326312)
- Testing
- GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
- Where
- 36 sites in United States
- Volunteers
- 159 people
- Sponsor
- GTx
Prostate Cancer
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated…
- Trial name
- NCT00946881
- Testing
- WST 11 -mediated -VTP
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Steba Biotech S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.